Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment — Stella

Home/Migraine/RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

View on ClinicalTrials.gov

Recruiting

Back to Migraine trials

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

Trial locations(2 sites)

Italy

SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi, Florence

IRCCS National Neurological Institute "C. Mondino" Foundation, Pavia

Key details

Sponsor

University of Florence

Collaborators

IRCCS National Neurological Institute "C. Mondino" Foundation, Società Italiana per lo Studio delle Cefalee

Enrollment target

~100 participants

Started

March 2024

Primary completion

January 2027

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.